Open-label Pilot Study of Interferon Gamma-1b (Actimmune™) for the Treatment of Friedreich Ataxia (FRDA)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Oct 2014 Results published in a Horizon Pharma media release.
13 Oct 2014 Results were presented at the the Children's Hospital of Philadelphia (CHOP) 7th Annual Friedreich's Ataxia (FA) Symposium and are being discussed at the Horizon analyst day, according to a Horizon Pharma media release.
09 Oct 2014 According to a Horizon Pharma media release, data was published in an abstract in Annals of Neurology and presented at the 139th Annual Meeting of the American Neurological Association.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com